Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 AKI study of Gemini

REVB•2026-08-19

Study timing remains unchanged

The study remains on track to start later this year.

Avance Clinical named CRO for TITAN study

Revelation Biosciences selected Avance Clinical as contract research organization for its Phase 2/3 adaptive-design TITAN study of Gemini in acute kidney injury.

Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 AKI study of Gemini

Study timing remains unchanged

Avance Clinical named CRO for TITAN study

Related News

Valens Semiconductor CFO Karine Pinto Flomenboim files initial beneficial ownership statement

Scinai Immunotherapeutics changes ADS ratio in move equivalent to 1-for-10 reverse split

Ppg Appoints Leaders Of Global Business Segments To Accelerate Growth And Productivity

HeartSciences sells 411,522 shares to Fortitude in USD 1 million private placement at USD 2.43 each

Amex halt MRVX add info LST 22.139600